Table 2.
Clinical and radiometabolic responses, pathologic and immunologic changes induced in the overall population by olaparib.
| Variables | Pre-olaparib | Post-olaparib | P* |
|---|---|---|---|
| Clinical Dimension (mm) | |||
| Median (Min - max) | 39 (18 - 80) | 20 (0 - 80) | <0.001 |
| Δ Clinical Dimension | |||
| Mean (SD) | - | -25.3 ( ± 24.5) | – |
| Clinical Response After Olaparib | |||
| Complete Response | – | 0 (0.0%) | – |
| Partial Response | – | 16 (45.7%) | |
| Stable Disease | – | 17 (48.6%) | |
| Progressive Disease | – | 2 (5.7%) | |
| PET/CT dimensions (mm) | |||
| Mean (SD) | 29.8 ( ± 17.4) | 25.9 ( ± 17.5) | 0.01 |
| SUVmax | |||
| Median (Min - max) | 9.3 (1.9 - 31.0) | 4.8 (1.0 - 23.8) | 0.004 |
| Δ SUVmax | |||
| Mean (SD) | – | -27.1 ( ± 49.3) | – |
| Radiometabolic Response After Olaparib | |||
| Complete Response | – | 0 (0.0%) | – |
| Partial Response | – | 15 (42.9%) | |
| Stable Disease | – | 9 (33.3%) | |
| Progression Disease | – | 3 (23.8%) | |
| Pathologic Response After Surgery | |||
| pCR | – | 8 (22.9%) | – |
| No pCR | – | 22 (62.9%) | |
| Not Available | – | 5 (14.2%) | |
| Ki67% | |||
| Median (min - max) | 50.0 (10 - 90) | 62.5 (0 - 90) | 0.67 |
| TILs | |||
| Median (min - max) | 40 (10 - 90) | 40 (0 - 90) | 0.77 |
Means with standard deviation are reported when the variable’s distribution was normal according to a Shapiro-Wilk test for normality, otherwise median values with minimum-maximum range are reported; Δ, Delta; Δ formula, (Post-therapy value - Baseline Value)/Baseline Value; SD, standard deviation; TILs, tumor-infiltrating lymphocytes; SUV, standard uptake volume; min, minimum; max, maximum. *, exploratory comparisons; pCR, pathologic complete response.